First low cost, in office, test to determine if a cancer regimen is working. A novel, method measures cancer DNA in the blood. 3:1 $ leverage/matching grant.
Cancer therapies may cost $10,000 or even $25,000 a month, they cause side effects and most importantly, they fail to work, or stop working, more often than they succeed. aiGENE will offer the first low cost, in office measurement to determine at the time of the first visit after treatment starts, rather than after months, if a therapy is working or if it should be changed to one more appropriate for that person.